STERIS Reports Q2 Revenue Growth and Announces Xodus Medical Acquisition
STERIS plc (STE) reported second-quarter revenue of $1.6 billion, representing a 9% increase on an as-reported basis. Organic revenue growth reached 8% when adjusted for constant currency, fueled by increased volume and pricing advantages. In addition to the quarterly results, the company announced its agreement to acquire Xodus Medical. Looking ahead, STERIS provided long-term guidance, forecasting fiscal year 2027 earnings per share (EPS) to fall within the range of $11.35 to $11.55.
Tickers: $STE
Topics: organic revenue quarterly earnings revenue growth
Read the full article at Seeking Alpha
Part of the story STERIS Reports Q2 2027 Growth Driven by Life Sciences and Tariff Refunds (2 articles)